Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932242 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
A Phase 1 study, sponsored by Elusys Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT01932242: Completed Phase 1 study, sponsored by Elusys Therapeutics.
NCT01932242 is a Phase 1 study that has completed, run by Elusys Therapeutics. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01932242, a Phase 1 study, has completed, sponsored by Elusys Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of repeat administration (two doses) of intravenous (IV) ETI-204.
Primary Outcome
Safety was assessed for all subjects in the safety population by collecting and monitoring vital signs, laboratory tests, ECGs, physical examinations, skin assessments, infusion site assessments and adverse events.
Interventions
- OTHER Placebo
- BIOLOGICAL ETI-204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2013-07-23 |
| Est. Completion | 2014-04-19 |
| Phase | Phase 1 |
What the finished NCT01932242 record still lists
NCT01932242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01932242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01932242 about?
NCT01932242 is a clinical study titled "Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers". To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of repeat administration (two doses) of intravenous (IV) ETI-204.
What is the current status of trial NCT01932242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2013-07-23. Estimated completion is 2014-04-19.
What interventions are being tested in trial NCT01932242?
The interventions under investigation include: Placebo (OTHER), ETI-204 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01932242?
This trial is sponsored by Elusys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01932242's enrollment target sits among peer trials
70 749th of 2000 higher than 1,227 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI